Oncology Institute Inc (TOI) Stock 2026 Review

Mika L.
Written by Mika L.
Financial Content Writer

Oncology Institute Inc3.0/5

TOI (NASDAQ)

Dividend yield
no dividend
1-Year Return
1135.16%
5-Year Return
-64.48%

Oncology Institute Inc (TOI) has delivered an impressive one-year return of 1135.16%, making it a standout performer in the market. However, investors should be cautious as the company’s five-year return is notably negative at -64.48%, raising questions about its long-term growth prospects. Analysts maintain a median price target of $5.00, suggesting a potential upside, but with projected revenue growth stagnating, TOI's future remains uncertain.

Pros:

  • Strong one-year return
  • Consensus rating of Strong Buy

Cons:

  • Stagnating revenue growth
  • Negative outlook for financial performance

Oncology Institute Inc (TOI) may be suitable for risk-tolerant investors looking for high-reward opportunities, given its remarkable one-year return of 1135.16%. However, potential investors should be wary of its significant five-year decline and the uncertainty surrounding its long-term growth prospects, necessitating a careful evaluation of their investment strategy.

Frequently Asked Questions